explore -WSS

explore

author：entertainment 2025-10-01 23:05:21 - browse：41

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Addressing health care workers' trauma can help fight burnout

focus

WSS

Listen: A conversation with researcher Kevin Esvelt on biosecurity

FDA's Woodcock to retire early next year

Poor hospice wound care hurts patients and families

CRISPR pioneers react to Casgevy, first gene

Gain of function research would be limited under House proposal

FDA's Woodcock to retire early next year

focus

explore

focus

New air purifier tech could be key to improving indoor air quality

Anthos stroke drug appears safer than common blood thinner

Novavax promises a turnaround & Lilly roils the obesity market

Gain of function research would be limited under House proposal

Malaria cases in Florida and Texas: Here’s what you need to know

Wegovy, Zepbound and weight loss drugs that preserve muscle

After affirmative action ruling, medical educators look to 'holistic review'

Childhood cancer progress stalls for Black, Hispanic kids: Report

Apple is now the first public company to be valued at $3 trillion

Surge of respiratory disease in China has likely explanation

entertainment

Does good food count as health care? Study aims to find out

Addressing health care workers' trauma can help fight burnout

In key trial, Verve's treatment lowers cholesterol levels in patients

ASCO eve: Let’s set the table for this year's meeting

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

CRISPR pioneers react to Casgevy, first gene

knowledge

focus

focus

hotspot